GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 970 participants.
Also called NCT01813422
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 970 participants
- Sponsor
- Registry
-
NCT01813422 -
2012-004208-37
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Czechia, Denmark, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, Norway, Philippines, Poland, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01813422. Randomized; quadruple masking; primary purpose treatment. Start 2013-04-18 (actual); primary completion 2016-07-12 (actual). Results posted on 2018-01-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
- Acronym
- GLAGOV
- Condition
- Hypercholesterolemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01813422- Content hash
5f3daeb60bedc849856190749d88f97e1d33fa9de9b64e0ea93ec85eefc089ea